Published 4 days ago • loading... • Updated 3 days ago

Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting

On March 25, 2025, Eli Lilly and Company, listed on the NYSE as LLY, announced it will present preclinical data for agents targeting SMARCA2 and multiple KRAS mutations at the American Association for Cancer Research Annual Meeting in Chicago.
Lilly, collaborating with Foghorn Therapeutics, aims to make life better for millions by turning science into healing, and will present data on LY4050784, a selective SMARCA2 inhibitor, in combination with chemotherapy, pembrolizumab and KRAS inhibitors, for SMARCA4 mutant cancers.
Lilly will also present preclinical data for LY4066434, an oral pan-KRAS inhibitor highly selective over HRAS and NRAS, demonstrating robust anti-tumor activity in KRAS-mutant models, including in the CNS.
Nathan Brooks will present Abstract 3779 regarding LY4050784 on Monday, April 28, from 2:30-4:30 p.m. CST during the 'Continuum of Innovation: Biological Therapeutic Agents' session, while Hong Gao will present on LY4066434 on Tuesday, April 29, from 9 a.m.-12 p.m.
Lilly's announcement contains forward-looking statements regarding its oncology pipeline and therapies under development, but the company undertakes no duty to update these statements and cautions that drug development involves substantial risks, with no guarantee of study completion, consistent results, regulatory approval, or commercial success.

Insights by Ground AI

Does this summary seem wrong?

26 Articles

All

Left

Center

Right

Wisconsin State Journal

+24 Reposted by 24 other sources

Center

Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting

INDIANAPOLIS, March 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS mutations will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking…

4 days ago·Madison, United States

Read Full Article

Elevation Oncology

Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025 - Elevation Oncology

- Abstract accepted for late-breaking poster presentation – -- EO-1022 is a potentially differentiated HER3 ADC being developed for the treatment of solid tumors, including breast and non-small...

3 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year